Progress of programmed death-1/programmed death-1 ligand in esophageal cancer
10.3760/cma.j.issn.1006-9801.2017.11.015
- VernacularTitle:程序性死亡受体1/程序性死亡受体1配体在食管癌中的研究进展
- Author:
Xiaocui XIE
1
Author Information
1. 川北医学院附属医院肿瘤科
- Keywords:
Esophageal neoplasms;
Programmed death-1;
Programmed death-1 ligand;
Tumor immunity
- From:
Cancer Research and Clinic
2017;29(11):776-780
- CountryChina
- Language:Chinese
-
Abstract:
Programmed death-1 (PD-1) occurs widely in a variety of human immune cells and tumor cells. When PD-1 is combined with programmed death-1 ligand (PD-L1), T-lymphocyte will be exhausted eventually resulting in tumor immune escape. Experiments in vitro and in vivo have demonstrated that inhibiting the binding of PD-1 with PD-L1, and blocking downstream signaling pathways can enhance endogenous anti-neoplastic immune effects. The expression of PD-1/PD-L1 is related to the clinical stage and prognosis of esophageal cancer patients, which may become the clinical biomarkers, serving as a new target for cancer immunotherapy.This paper reviews the relationship between PD-1/PD-L1 and esophageal cancer as well as the related treatment progress.
